The European Commission has granted conditional marketing authorization (Aic) for idecabtagene vicleucel (Ide-cel), the first T-cell based immunotherapy with chimeric antigen receptor (Car-T) directed against maturation antigen B cell (Bcma), for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and who have demonstrated disease progression to the last therapy. This was announced by Bristol Myers Squibb (Bms), noting that Ide-cel is the first and only approved Car-T therapy aimed at recognizing and binding to Bcma, a protein almost universally expressed on multiple myeloma cells, killing diseased cells.
Read Also
- Don’t just go back to “normal”. Your life after the pandemic can be better May 31, 2021
- In Sweden, no masks, no school closures, and the epidemic is at its lowest Aug 6, 2020
- 200,000 Cansino vaccines have arrived against the coronavirus: they will be applied to homeless people and refugees Sep 7, 2021
- Called healing properties of black pepper Jul 16, 2020
- None of the twelve ICU patients in the Region is vaccinated Jul 15, 2021
- Alcohol, drugs, gambling and … addictions now have a hope of healing Jul 10, 2021
- WHO recognizes the lack of knowledge about monkeypox, but says that “it is not to worry” and that “it is not Covid” May 28, 2022